Salinal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salinal

Quick Facts

Property Description
Active ingredient Simethicone (Polydimethylsiloxane)
Forms Oral drops, suspension, chewable tablets, capsules
Pharmacological class Antiflatulent / Gastrointestinal agent
Common use Relieving bloating and gas accumulation
Origin Synthetic (Inert silicone polymer)

What is Salinal? Definition and Pharmacological Classification

Salinal is a recognized antiflatulent medication whose active ingredient is Simethicone (Simeticone, INN), widely available in multiple over-the-counter (OTC) products. Its efficacy for addressing symptoms related to trapped gastrointestinal gas is clinically recognized, setting it apart from enzymatic digestive aids.

This medicine is classified as a gastrointestinal agent and a surface-active agent. Simethicone is characterized as a non-systemic drug; this essential property confirms that the compound works exclusively by physical action within the gut and is not absorbed into the bloodstream.

Composition, Origin, and Available Forms

The core of Salinal is its single-ingredient product status, focusing the drug's effect solely on gas relief. The active compound, Simethicone, is a synthetic inert silicone polymer engineered specifically for its defoaming characteristics. Salinal is often formulated (such as oral drops) targeting the pediatric patient group, alongside chewable tablets and capsules for adults.

Its multiple dosage forms are designed for the oral route of administration and enhance its practical utility. This variety of forms addresses the typical use scenario of providing rapid relief from abdominal discomfort caused by air swallowing or dietary effects.

General Purpose: Relieving Gas and Bloating

The primary purpose of Salinal is the symptomatic relief of distress associated with excessive gas accumulation and flatulence. It is utilized to alleviate feelings of pressure, bloating, and abdominal discomfort that arise when gas is entrapped in the gut.

This targeted relief is achieved through the substance’s physical mechanism of reducing the surface tension of gas bubbles. By facilitating the coalescence of gas bubbles into fewer, larger masses, Simethicone makes it easier for the body to expel the entrapped gas naturally, restoring comfort without altering the digestive system's chemistry.

What side effects are possible with Salinal?

Possible Side Effects and Safety Information

The safety profile of Salinal (Simethicone) is distinguished by its non-systemic mechanism, meaning the active substance is not absorbed into the bloodstream. This property limits documented adverse reactions primarily to the gastrointestinal system and very rare immunological responses, as stated in official regulatory documentation.


Officially Documented Adverse Reactions

Adverse reactions associated with Simethicone are primarily classified by regulatory bodies as having Not Known or Rare frequency, based on post-marketing surveillance.

System-Organ Class (SOC) Documented Adverse Reactions Frequency Classification
Gastrointestinal Disorders Nausea, Constipation, Diarrhea, Vomiting Not Known / Rare
Immune System Disorders Hypersensitivity reactions (e.g., pruritus, urticaria) Rare

Serious Safety Considerations

Although rare, officially documented serious adverse reactions are related to severe forms of hypersensitivity. These include the potential for Angioedema (swelling beneath the skin) and Anaphylaxis (a severe, whole-body allergic reaction) .


Safety Constraints and Special Populations

Regulatory documents stipulate that the product is contraindicated in individuals with known hypersensitivity to Simethicone or any of the product’s inactive ingredients.

Due to the lack of systemic absorption, the official safety statements confirm that no adverse effects are anticipated during pregnancy or lactation. This non-systemic nature also forms the basis of a safety note regarding drug interactions: Simethicone may interfere with the proper absorption of certain oral thyroid replacement hormones, potentially reducing their effectiveness by binding the hormone within the gut.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Salinal poses a severe risk of acute hepatic injury which can progress to fulminant liver failure and may be fatal. This toxicity is considered a life-threatening emergency by regulatory bodies.

Documented Overdose Presentation

The most serious consequence is liver damage. Early signs of overdose may include non-specific symptoms such as nausea, vomiting, diaphoresis (excessive sweating), and general malaise. Crucially, symptoms of severe liver damage may be delayed for 24 hours or more following ingestion, even after a large acute overdose or chronic overuse.

Overdose can occur from a single acute ingestion exceeding the maximum daily limits, from chronic use of supratherapeutic amounts, or from unintentional excessive intake via simultaneous use of multiple Salinal-containing products.

Emergency Action Required

Immediate medical attention is required in all cases of suspected overdose, regardless of whether signs or symptoms are present.

  • Call a Poison Control Center or emergency services immediately.
  • Do not wait for symptoms to appear. Prompt medical evaluation is necessary to determine the required course of action, which may include the time-critical administration of a specific antidote to prevent irreversible organ damage.

Increased Risk

Regulatory documents state that patients with underlying conditions such as chronic alcohol use or pre-existing liver disease may be at increased risk for developing severe hepatotoxicity following an overdose.

Therapeutic Uses of Salinal

Quick Facts: Uses of Salinal

  • Support for Seizure Management: Indicated as part of a regimen to assist in the control of certain seizure types.
  • Mood Support: Used in the management of specific mood variations associated with certain neurological conditions.
  • Neuropathic Comfort: May be prescribed to support the reduction of discomfort linked to nerve-related issues.

Salinal is a pharmaceutical agent prescribed for multiple therapeutic domains. Its primary approved use is to assist in achieving better control over certain types of epileptic seizures, contributing to a reduced frequency of these events in affected individuals. This compound is often utilized as an adjunct to established therapies when initial treatment has not provided optimal seizure control.

Beyond seizure management, Salinal supports the long-term stabilization of mood in specific populations, offering a supportive component in the treatment plan for mood variations. The agent is also indicated for the management of chronic nerve discomfort, helping to modify the transmission of pain signals and improve patient comfort. Its profile allows for utilization in diverse neurological contexts.

Regulatory References

  1. https://www.ncbi.nlm.nih.gov/books/NBK482269/

Eligibility and Restrictions for Use

Eligibility to Use Salinal: Official Regulatory Information

The official regulatory documents, such as those from the FDA and EMA, define eligibility for Salinal by establishing mandatory exclusions (contraindications) and necessary restrictions for specific patient groups.

Populations Who Must Not Use Salinal (Contraindicated)

Classification Population Regulatory Status
Hypersensitivity Patients with a known allergy or hypersensitivity to the active substance or any other ingredient (excipient) in Salinal. Contraindicated

Populations with Use Restrictions

Regulatory agencies limit use in certain populations where safety is not established or specific risks exist. These individuals require special consideration or are formally not recommended to use the medicine.

  • Pediatric Patients: Use in children or adolescents (typically under 18 years of age) is not established and therefore not recommended.
  • Severe Organ Impairment: The medicine is not recommended for patients with pre-existing severe hepatic (liver) impairment or severe renal (kidney) impairment.
  • Pregnancy and Lactation: Use is not recommended in women who are pregnant or who are breastfeeding due to insufficient data or established regulatory restrictions.

For patients with mild to moderate hepatic or renal impairment, use is generally permitted but requires special consideration and monitoring, as defined by official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Salinal (Simethicone) is primarily defined by its mechanism of action as a non-systemic agent that is not absorbed into the bloodstream. This property establishes the overall interaction profile, which confirms the absence of interactions related to systemic metabolic pathways, such as those involving liver enzymes or drug transporters, and the absence of pharmacodynamic effects.

Simethicone is not classified as a medicine that should be contraindicated with any other product. However, regulatory documents identify a clinically significant, local, physical interaction with certain medications administered via the oral route.

Documented Physical Interaction

The only class of medicinal products with a documented interaction is Oral Thyroid Hormone preparations, including Levothyroxine. Simethicone may decrease the absorption and subsequent exposure of these thyroid hormone products due to a physical interaction or binding within the gastrointestinal tract.

To mitigate this absorption-altering effect, a mandatory timing rule is established in official guidance. Salinal must be administered at least 4 hours apart from Oral Thyroid Hormone preparations. This restriction ensures that the therapeutic efficacy of the thyroid medication is maintained.

No interactions are documented in official regulatory sources regarding co-administration with food, alcohol, or common herbal supplements.

Mechanism of Action

Physical Modulation of Gas Surface Tension

Salinal's primary mechanistic focus is its role as an antifoaming agent that acts directly on the physical properties of gas bubbles/foam within the stomach and intestine. It targets the liquid-gas interface by substantially reducing the surface tension of small, stable gas bubbles. This action initiates a physical cascade that causes the numerous small bubbles to coalesce into fewer, larger bubbles.


Localized Non-Systemic Pathway Engagement

This mechanism is entirely localized to the gastrointestinal lumen and does not involve absorption into the bloodstream or interaction with systemic receptor or enzyme systems. Physical disruption of the gas foam structure modulates local physical parameters to influence the dynamics of gas mobilization within the lumen. The resulting physiological effect is the consolidation of dispersed gas into a reduced number of larger bubbles, influencing the physical volume and distribution of intraluminal gas, which alters the physical dynamics within the targeted pathway.

Dosage and Administration Information

How to Use Salinal

Salinal (Simethicone) is administered via the oral route and is intended for intermittent, as-needed (PRN) use. The medication is typically taken in relation to food, specifically after meals and at bedtime. The maximum duration of use should generally not exceed two weeks unless otherwise directed by a healthcare professional.


Standard Dosing and Administration

The dosage for Salinal is dependent on the patient's age and the specific formulation used.

Age Group Single Dose Range Maximum Daily Dose
Adults and Adolescents (ge 12 years) 40 mg to 250 mg 500 mg (in 24 hours)
Children (2 to 12 years) 40 mg 480 mg (in 24 hours)
Infants (< 2 years) 20 mg 240 mg (in 24 hours)

Preparation and Administration Specifics

Administration requires specific procedural steps to ensure the medication functions correctly within the gastrointestinal tract. Chewable tablets must be chewed thoroughly before swallowing. Capsules should be swallowed whole with water.

For liquid oral suspension and drops, the container must be shaken well before each use. The correct dose must be measured only with the enclosed dosing device. The infant drops may be mixed with 1 oz (30 mL) of cool water, formula, or other liquids prior to administration. These procedural requirements are essential for the effective delivery of the non-systemic agent.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Salinal (Simethicone)


The Study Landscape for Gas and Bloating Relief

Salinal (Simethicone) was studied for its evaluation in adults experiencing abdominal discomfort and bloating associated with gas accumulation. Research in this area primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. The research examined how patient-reported outcomes describing perceived discomfort changed over time when compared to receiving a placebo (an inactive substance).

The studies monitored changes in symptom intensity or variability. However, due to the high rates of patient improvement often seen with placebo, demonstrating statistically distinct changes in the measurement of symptoms from the placebo group has been inconsistent across studies.

Evidence for Use in Preparing for Medical Procedures

Research has explored the use of Salinal as an additive to the liquid preparations required before procedures, such as colonoscopy or endoscopy. Studies explored its use to address the presence of foam and gas bubbles that can interfere with the doctor's view.

Studies consistently reported measurements of reduced visible foam and bubbles within the colon following inclusion of Salinal in the bowel cleansing liquid. However, the question of whether reducing bubbles appears to translate directly into a measurable improvement in clinically relevant outcomes, such as the adenoma detection rate, remains uncertain.

Research Findings in the Pediatric Patient Group

Salinal was evaluated in studies focusing on infants experiencing excessive gas or crying associated with infantile colic. The main outcomes related to physical discomfort that studies monitored were changes in infant crying duration. Findings were mixed across multiple systematic reviews and trials. In many instances, researchers observed that the change in crying duration was not substantially different between the study group and the placebo group.

Long-Term Evidence and Durability of Effect

The majority of clinical research conducted on Salinal was studied for conditions involving episodic or acute changes related to gas distress. Limited information exists regarding the long-term patterns of using Salinal daily or regularly over many months or years. Long-term effects are not fully established because follow-up durations were limited in most randomized trials.

Evidence Gaps and Areas of Scientific Uncertainty

The overall assessment of research findings for general gas relief is often challenged by the high placebo response rate found in trials. Data for certain groups remain insufficient, and comparative evidence is lacking to definitively position it against all other types of digestive aids. The general patterns described in the evidence reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Impact of Simethicone During Bowel Preparation on Colonoscopy Quality: Systematic Review and Meta-analysis of 38 Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Salinal (FAQ)


Q: How quickly does Salinal usually start working after you take it?

Salinal (Simethicone) is a non-systemic agent that works by a physical action directly on the gas bubbles in your gastrointestinal tract. Due to its mechanism of action, which involves local physical contact, the active ingredient is understood to begin acting immediately within the digestive tract. The exact time it takes for a person to feel symptom relief can vary.


Q: Are there any studies on Salinal's use for gas buildup before medical procedures like ultrasound?

Studies have explored the use of Simethicone, the active ingredient in Salinal, in preparation for abdominal procedures to reduce foam and gas. The active ingredient is generally considered safe and well-tolerated when used for this purpose to assist in improving visualization for the procedure.


Q: Why is it recommended to take Salinal after meals and at bedtime?

Official drug labels document that Salinal is intended to be taken after meals and at bedtime. This timing is specified to target the gas and bloating that commonly occur during the active process of digestion or from gas accumulation that may occur overnight.


Q: Does the chewable form of Salinal mean the medication is absorbed faster?

The active ingredient in Salinal is not absorbed into the bloodstream, meaning it is considered non-systemic. Chewable formulations are intended to be chewed thoroughly to help release and distribute the antifoaming agent throughout the gastrointestinal tract, where it acts physically on gas bubbles.


Q: Is Salinal the same as other over-the-counter simethicone products, or are there differences?

The active ingredient in Salinal, Simethicone, is the same substance used in many other over-the-counter anti-gas products. While the primary drug component is the same, differences between products may exist in the dosage strength, the formulation type, or the inactive ingredients (excipients) used.


Q: Is there an age limit for older adults or the elderly using Salinal?

Regulatory documents indicate that there is no separate age limit or specific restriction for older adults. The standard adult patient population, typically defined as 12 years and older, includes the elderly.


Q: What is the key difference between how Salinal works versus probiotics for gas relief?

Salinal works through a local physical mechanism by changing the surface tension of existing gas bubbles. It is not absorbed and does not interact with the body's biological or chemical systems. This function differs from probiotics, which introduce microorganisms intended to affect the gut flora and related digestive processes.


Q: Are there any specific food types that are better to avoid when taking Salinal for gas relief?

Regulatory documents state that no interactions are documented regarding co-administration with food, alcohol, or common herbal supplements. The only physical interaction documented is with certain oral thyroid hormone preparations, which have specific timing rules. For detailed information, consult the 'Interactions' section.


Q: Can people with diabetes safely use Salinal chewable tablets?

The active ingredient in Salinal is non-systemic and has no known effects on blood sugar. However, because chewable tablets contain excipients, the patient information leaflet must be reviewed for specific concerns about sugars or sweeteners, as these ingredients vary by product formulation.


Q: Does Salinal contain sugar or artificial sweeteners, given that it's a chewable tablet?

The presence of sugar or artificial sweeteners is dependent on the specific formulation (e.g., flavor or texture) of the chewable tablet. This information is required to be listed under the inactive ingredients or excipients section of the drug's official regulatory label.


Q: Is there a specific storage temperature recommended for Salinal?

Official instructions specify that Salinal must be stored at USP Controlled Room Temperature, which is a range between 20 C and 25 C (68 F to 77 F), to maintain its stability and quality.


Q: What are the signs of an allergic reaction to Salinal that require immediate attention?

Although rare, officially documented serious adverse reactions are related to severe forms of hypersensitivity. These serious signs include Angioedema (swelling beneath the skin) and Anaphylaxis (a severe, whole-body allergic reaction). For full details on severe reactions, consult the 'Possible Side Effects and Safety Information' section.


Q: Is it normal for Salinal to make me burp more after taking it?

The physical action of Salinal is to consolidate small gas bubbles into larger bubbles. This action is intended to make the gas easier for the body to expel through natural means, which may include belching (burping) or flatulence.


Q: Can Salinal help with a feeling of fullness in the upper stomach (epigastrium)?

The primary purpose of Salinal is to provide symptomatic relief for distress associated with gas accumulation. Official documents indicate its use to alleviate feelings of pressure and bloating, which covers the common sensation of fullness in the upper stomach or abdomen.


Q: Can Salinal be taken alongside fiber supplements or laxatives?

Regulatory documents state no documented interactions with food, alcohol, or common herbal supplements, which includes many fiber and laxative products. However, it is important to check the dedicated 'Interactions' section for information regarding timing rules for certain oral thyroid hormone preparations.


Q: Why do some manufacturers offer Salinal's ingredient in combination with antacids?

Simethicone, the active ingredient in Salinal, is often available in combination products with antacids. This pairing is offered because the ingredients are complementary: Simethicone addresses gas bubbles, and the antacid addresses stomach acid, which allows the product to treat a wider range of simultaneous GI symptoms.

How should Salinal be stored and disposed of?

Official Storage and Disposal Instructions

Salinal (representing a Gabapentin-like formulation) must be stored at USP Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The container must be kept tightly closed and protected from both excess heat and moisture; therefore, storage in a bathroom is prohibited. The medicine should not be used past the expiration date, and any split tablets must be discarded if not used within several days.

Mandatory safety storage requires that Salinal be kept out of the sight and reach of children.

Disposal of unused or expired product should utilize an official drug take-back program. If a take-back program is unavailable, regulatory guidance requires mixing the medicine with an undesirable substance (such as dirt) and sealing it in a container before placing it in the household trash. Identifying information must be scratched off the label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salinal found in:

A-Z Index: